Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system. Tan Y, Song Q. BMC Cancer 2025;25:1360.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tan Y, Song Q. Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system. BMC Cancer 2025;25:1360.
PMID: 40846919